GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » European Biotech Acquisition Corp (NAS:EBACU) » Definitions » Total Liabilities

EBACU (European Biotech Acquisition) Total Liabilities : $8.55 Mil (As of Dec. 2022)


View and export this data going back to 2021. Start your Free Trial

What is European Biotech Acquisition Total Liabilities?

European Biotech Acquisition's Total Liabilities for the quarter that ended in Dec. 2022 was $8.55 Mil.

European Biotech Acquisition's quarterly Total Liabilities increased from Jun. 2022 ($5.65 Mil) to Sep. 2022 ($6.53 Mil) and increased from Sep. 2022 ($6.53 Mil) to Dec. 2022 ($8.55 Mil).

European Biotech Acquisition's annual Total Liabilities increased from . 20 ($0.00 Mil) to Dec. 2021 ($7.61 Mil) and increased from Dec. 2021 ($7.61 Mil) to Dec. 2022 ($8.55 Mil).

European Biotech Acquisition Total Liabilities Historical Data

The historical data trend for European Biotech Acquisition's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

European Biotech Acquisition Total Liabilities Chart

European Biotech Acquisition Annual Data
Trend Dec21 Dec22
Total Liabilities
7.61 8.55

European Biotech Acquisition Quarterly Data
Jan21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Total Liabilities Get a 7-Day Free Trial 7.61 6.15 5.65 6.53 8.55

European Biotech Acquisition Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

European Biotech Acquisition's Total Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.796+(0+1.32
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+6.432+0+0)
=8.55

Total Liabilities=Total Assets (A: Dec. 2022 )-Total Equity (A: Dec. 2022 )
=129.753-121.204
=8.55

European Biotech Acquisition's Total Liabilities for the quarter that ended in Dec. 2022 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.796+(0+1.32
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+6.432+0+0)
=8.55

Total Liabilities=Total Assets (Q: Dec. 2022 )-Total Equity (Q: Dec. 2022 )
=129.753-121.204
=8.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

European Biotech Acquisition Total Liabilities Related Terms

Thank you for viewing the detailed overview of European Biotech Acquisition's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

European Biotech Acquisition Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » European Biotech Acquisition Corp (NAS:EBACU) » Definitions » Total Liabilities
Comparable Companies
CNTQ LION MEOA SCMA LATG NBST CCTS FRBN NMMC DMAQ GSHN PSTH XAMS:EPIC ASZ CCYC CVII KAHC DWAC IPOF PBAJ
Traded in Other Exchanges
N/A
Address
EPFL Innovation Park Building, Lausanne, CHE, 1015
Website
https://www.lspvc.com
European Biotech Acquisition Corp is a blank check company.
Executives
Mohammad Sohail Fazeli director JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Martijn Kleijwegt director JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Volkert H. Doeksen director RIOUWSTRAAT 10, THE HAGVE P7 2585HA
Fernandez De Araoz Eduardo Bravo officer: Chief Executive Officer JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Koen Sintnicolaas officer: Chief Financial Officer JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Lsp Sponsor Ebac B.v. 10 percent owner JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Van De Stolpe Onno director JOHANNES VERMEERPLEIN 9, AMSTERDAM, P7 1071 DV
Marcus Antonius Wegter director JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Lsp Management Group B.v. 10 percent owner JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV